Table 3.
BPDAI score, anti BP180 autoantibody titres, and anti BP230 autoantibody titres in patients who revealed a clinical relapse at different time points.
| Case | Baseline | Month 3 | Month 6 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| BPDAI | BP180 | BP230 | BPDAI | BP180 | BP230 | BPDAI | BP180 | BP230 | |
| 1 | 2.0 | 27.0 | 5.0 | 0.0 | 5.3 | 4.6 | 14.4 | 36.1 | 21.0 |
| 2 | 36.0 | 141.4 | 5.5 | 6.0 | 35.6 | 6.1 | 0.0 | 6.9 | 7.1 |
| 3 | 76.0 | 77.2 | 11.0 | 10.9 | 32.1 | 13.0 | 0.0 | 6.9 | 9.0 |
| 4 | 2.0 | 10.6 | 6.1 | 0.0 | 2.4 | 6.0 | 16.1 | 38.9 | 15.1 |
| 5 | 84.0 | 100.8 | 19.6 | 13.3 | 34.9 | 20.1 | 0.0 | 4.4 | 8.9 |
| 6 | 2.0 | 10.0 | 3.6 | 0.0 | 3.1 | 2.9 | 17.1 | 41.1 | 17.7 |
| 7 | 50.0 | 98.2 | 34.4 | 15.5 | 36.7 | 32.2 | 0.0 | 8.6 | 13.2 |
| 8 | 56.0 | 120.3 | 37.9 | 0.0 | 8.8 | 16.9 | 12.2 | 29.9 | 25.9 |
| 9 | 64.0 | 93.2 | 31.7 | 11.2 | 41.9 | 30.3 | 0.0 | 7.7 | 24.1 |
| 10 | 82.0 | 118.2 | 17.8 | 14.4 | 49.1 | 21.2 | 0.0 | 6.7 | 15.6 |